Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, May 23, 2025 (HealthDay News) — Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in confirmatory trials, with a lower dose of medication, according to a study published online May 12 in The Lancet Digital Health<\/em> to coincide with the annual meeting of the European Congress on Obesity, hosted by the European Association for the Study of Obesity, from May 11 to 14 in Malaga, Spain.<\/p>\n S\u00f8ren Seier, from the University of Copenhagen in Denmark, and colleagues examined the effectiveness of an online multidisciplinary weight loss service combining personalized semaglutide doses with IBT in a retrospective cohort study. The study included 2,694 participants who were treated with semaglutide and IBT including personalized evidence-based recommendations on nutrition, exercise, and habits through an online app (The Embla app).<\/p>\n Overall, 1,580, 712, and 465 participants were still included after 26, 52, and 64 weeks, respectively. The researchers found that after 64 weeks, participants had a mean weight loss of \u221216.7 percent, with a mean semaglutide dose of 1.08 mg\/week. Weight loss of at least 5 and 10 percent was achieved by 98 and 83 percent of participants, respectively. Across baseline body mass index class subgroups and across mean medication doses, there was a similar percentage change in body weight.<\/p>\n \u201cOur results show that by giving personalized doses of semaglutide along with diet, exercise, and psychological support, it is possible for patients to achieve clinical trial-level weight loss in their day-to-day lives,” Henrik Gudbergsen, M.D., lead researcher and chief medical officer of Embla, said in a press release. \u201cOur \u2018treat-to-target\u2019 approach, in which amount of medication was tailored to each patient\u2019s goals, allowed us to keep doses as low as possible, which should mean lower costs and fewer side-effects for patients.\u201d<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Embla ApS, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n